| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalaris Therapeutics, Inc. (KLRS) has 2 insiders with recent SEC Form 4 filings, including 0 buys and 11 sells. KLRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 2.22M | $10.36M | - | |
| CFO | 235.0K | $1.10M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 23, 2024 | Sinha Vikas84 | See Remarks | Sell | 3,205 | $0.67 | $2,149.91 | -0.3% | +13.9% | -40.3% | |
| Jan 23, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 9,500 | $0.67 | $6,368.80 | -1.1% | +13.9% | -40.3% | |
| Jan 23, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 901 | $0.67 | $604.39 | -0.9% | +13.9% | -40.3% | |
| Jan 23, 2024 | Miller Edward82 | General Counsel | Sell | 1,302 | $0.67 | $873.38 | -0.6% | +13.9% | -40.3% | |
| Jan 4, 2024 | Miller Edward82 | General Counsel | Sell | 424 | $0.64 | $270.94 | -0.2% | +14.3% | -32.4% | |
| Jan 4, 2024 | Sinha Vikas84 | See Remarks | Sell | 961 | $0.64 | $614.08 | - | +14.3% | -32.4% | |
| Jan 4, 2024 | Brainard Diana85 | Chief Executive Officer | Sell | 1,664 | $0.64 | $1,063.30 | -0.2% | +14.3% | -32.4% | |
| Jan 4, 2024 | Hagen Brett R84 | Chief Accounting Officer | Sell | 310 | $0.64 | $198.09 | -0.3% | +14.3% | -32.4% | |
| Dec 27, 2023 | Hagen Brett R84 | Chief Accounting Officer | Sell | 28,335 | $0.74 | $20,837.56 | -22.5% | +7.3% | -32.3% | |
| Nov 20, 2023 | Brainard Diana85 | Chief Executive Officer | Sell | 7,071 | $1.67 | $11,793.80 | -0.4% | -57.1% | -65.9% |